RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of BCRX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

BioCryst Pharmaceuticals stock price ended at $5.08 on Thursday, after losing 1.36%.
(Updated on Mar 28, 2024)

Sell candidate since Mar 22, 2024 Gain 1.40% PDF

The BioCryst Pharmaceuticals stock price fell by -1.36% on the last day (Thursday, 28th Mar 2024) from $5.15 to $5.08. During the last trading day the stock fluctuated 5.53% from a day low at $5.06 to a day high of $5.34. The price has risen in 7 of the last 10 days and is up by 3.89% over the past 2 weeks. Volume has increased on the last day by 958 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 3 million shares were bought and sold for approximately $17.66 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -15.82% during the next 3 months and, with a 90% probability hold a price between $3.63 and $5.49 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

BCRX Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, March 14, 2024, and so far it has risen 3.89%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The BioCryst Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $5.16 and $5.43. A break-up above any of these levels will issue buy signals. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for BioCryst Pharmaceuticals stock

BioCryst Pharmaceuticals finds support from accumulated volume at $5.01 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.280 between high and low, or 5.53%. For the last week, the stock has had daily average volatility of 5.69%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (BCRX) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect BioCryst Pharmaceuticals to open at $5.16, and during the day (based on 14 day Average True Range), to move between $4.77 and $5.39, which gives a possible trading interval of +/-$0.312 (+/-6.15%) up or down from last closing price. If BioCryst Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 12.30% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $5.14 (1.18%) than the support at $5.01 (1.38%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is BioCryst Pharmaceuticals stock A Buy?

BioCryst Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.770 Sell Candidate Unchanged

Predicted Opening Price for BioCryst Pharmaceuticals of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$5.16 ( 1.57%) $5.08

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for BCRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.44 7.09 %
R2 5.33 4.98 %
R1 5.27 3.68 %
Current price: 5.08
Support S1 5.05 -0.531 %
S2 4.99 -1.83 %
S3 4.88 -3.94 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.62 10.63 %
R2 5.32 4.72 %
R1 5.14 1.18 %
Current price 5.08
Support S1 5.01 -1.38%
S2 5.00 -1.57%
S3 4.89 -3.74%

FAQ

What is the symbol for BioCryst Pharmaceuticals Stock and on which exchange is it traded?
The symbol for BioCryst Pharmaceuticals is BCRX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell BioCryst Pharmaceuticals Stock?
BioCryst Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy BioCryst Pharmaceuticals Stock?
BioCryst Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy BioCryst Pharmaceuticals Stock.

What's the current price of BioCryst Pharmaceuticals Stock?
As of the end of day on the 2024-03-28, the price of an BioCryst Pharmaceuticals (BCRX) share was $5.08.

What is the 52-week high and low for BioCryst Pharmaceuticals Stock?
The 52-week high for BioCryst Pharmaceuticals Stock is $9.07 and the 52-week low is $4.82.

What is the market capitalization of BioCryst Pharmaceuticals Stock?
As of the 2024-03-28, the market capitalization of BioCryst Pharmaceuticals is 1.062B.

When is the next earnings date for BioCryst Pharmaceuticals?
The upcoming earnings date for BioCryst Pharmaceuticals is May 01, 2024.
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT